Oncology R&D
Oncology R&D activity continues to grow driven by novel modalities. Novel modalities, especially cell and gene therapies, antibody-drug conjugates (ADCs), and multispecific antibodies, now account for 35% of oncology trials. Multiple novel modalities are evolving rapidly with significant potential both alone and in combination with each other.
Ensuring chemical cybersecurity
Our economy and society rely on a wide range of digital infrastructure, yet these critical systems are under unprecedented threat. Recent UK Government research reveals that approximately half of UK businesses have faced a cyber-attack in the past year, drawing attention to the critical need for enhanced cybersecurity strategies.
Opportunities for 3-D bioprinting
Healthcare-associated infections remain a significant concern in modern medicine, with approximately 1-in-31 hospital patients in the US experiencing at least one infection on any given day. These infections, along with surgical complications and immune rejection of transplants, contribute to extended recovery times, increased healthcare costs and higher mortality rates. In the EU alone, more than 3.5m cases of HAI are reported each year, leading to more than 90,000 deaths annually.